Lilly Points To Six-Month Growth Instead Of Pandemic Impacted Q2
Executive Summary
Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.